No Data
Sichuan Huiyu Pharmaceutical Secures Overseas Market Approvals for Key Products
Huiyu Pharma's Calcium Folinate Injection Gets Registration Certificate
2024 Annual Results Forecast
Huiyu Pharmaceutical (688553.SH): The net profit for 2024 is expected to increase by 114.61% to 157.54%.
Gelonghui January 24丨Huiyu Pharmaceutical (688553.SH) announced the annual performance forecast for 2024, expecting the net income attributable to owners of the parent company to be between 300 million yuan and 360 million yuan, an increase of 114.61% to 157.54% compared to the same period last year (statutory disclosure data). It is expected that the net income attributable to owners of the parent company, after deducting non-recurring gains and losses, will be between 95 million yuan and 110 million yuan, an increase of 43% compared to the same period last year (statutory disclosure data).
Sichuan Huiyu Pharmaceutical Obtains Ireland's Marketing Authorization for Anti-Infection Drug
Huiyu Pharmaceutical (688553.SH): Injectable teicoplanin has obtained marketing authorization in Ireland.
On January 16th, Gelonghui announced that its wholly-owned subsidiary Seacross Pharma (Europe) Ltd. has recently received the market license for the company's injectable Teicoplanin from the Irish Medicines Regulatory Authority. Injectable Teicoplanin is primarily used for treating parenteral infections in adults and children, such as complex skin and soft tissue infections, bone and joint infections, acquired pneumonia, urinary tract infection complications, infectious endocarditis, and peritoneal dialysis-related peritonitis, as well as bacteremia associated with the above symptoms. The product can also be used to treat.
Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
